Misplaced Pages

Lunresertib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyNext edit →Content deleted Content addedVisualWikitext
Revision as of 08:33, 28 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,704 edits created drug stubTag: nowiki added  Revision as of 10:15, 28 December 2024 edit undoGraeme Bartlett (talk | contribs)Administrators249,644 edits added Category:3-Hydroxyphenyl compounds using HotCatNext edit →
Line 119: Line 119:
] ]
] ]
]

Revision as of 10:15, 28 December 2024

Pharmaceutical compound
Lunresertib
Clinical data
Other namesRP-6306
Identifiers
IUPAC name
  • 2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethylpyrrolopyridine-3-carboxamide
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC18H20N4O2
Molar mass324.384 g·mol
3D model (JSmol)
SMILES
  • CC1=C(C(=C(C=C1)O)C)N2C(=C(C3=C2N=C(C(=C3)C)C)C(=O)N)N
InChI
  • InChI=InChI=1S/C18H20N4O2/c1-8-5-6-13(23)10(3)15(8)22-16(19)14(17(20)24)12-7-9(2)11(4)21-18(12)22/h5-7,23H,19H2,1-4H3,(H2,20,24)
  • Key:ARBRHWRTXPWZGN-UHFFFAOYSA-N

Lunresertib is an investigational new drug that is being evaluated for the treatment of cancer. It is an oral small molecule inhibitor of PKMYT1, developed by Repare Therapeutics. This drug targets cell cycle regulation in tumors with specific genetic alterations, including CCNE1 amplifications or FBXW7 and PPP2R1A loss of function mutations. It is currently in phase 1/2 clinical trials, both as monotherapy or in combination with camonsertib, an ATR inhibitor.

References

  1. Szychowski J, Papp R, Dietrich E, Liu B, Vallée F, Leclaire ME, et al. (August 2022). "Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306". Journal of Medicinal Chemistry. 65 (15): 10251–10284. doi:10.1021/acs.jmedchem.2c00552. PMC 9837800. PMID 35880755.
  2. Previtali V, Bagnolini G, Ciamarone A, Ferrandi G, Rinaldi F, Myers SH, et al. (July 2024). "New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives". Journal of Medicinal Chemistry. 67 (14): 11488–11521. doi:10.1021/acs.jmedchem.4c00113. PMC 11284803. PMID 38955347.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: